Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 5/4/2020
SIETES contiene 92957 citas

 
 
 1 a 20 de 279 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Vozoris NT, Wang X, Austin PC, Stephenson AL, O'Donnell DE, Gershon AS, Gill SS, Rochon PA. Serotonergic antidepressant use and morbidity and mortality among older adults with COPD. European Respiratory Journal 2018;52:1800475. [Ref.ID 102918]
2.Enlace a cita original Cita con resumen
Anónimo. Indacaterol for chronic obstructive pulmonary disease. Therapeutics Letter 2016:1-2. [Ref.ID 101043]
3. Cita con resumen
Anónimo. Alternatives to fluoroquinolones. Med Lett Drugs Ther 2016;58:75-6. [Ref.ID 100457]
4.Tiene citas relacionadas
Donohue JF. Another choice for prevention of COPD exacerbations. N Engl J Med 2016;374:2284-6. [Ref.ID 100406]
5.Tiene citas relacionadas Cita con resumen
Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, Thach C, Fogel R, Patalano F, Vogelmeier CF. Indacaterol–glycopyrronium versus salmeterol–fluticasone for COPD. N Engl J Med 2016;374:2222-34. [Ref.ID 100405]
6. Cita con resumen
Matera MG, Rogliani P, Calzetta L, Cazzola M. Safety considerations with dual bronchodilator therapy in COPD: an update. Drug Saf 2016;39:501-8. [Ref.ID 100371]
7.Enlace a cita original Cita con resumen
Kirchmayer U, Cascini S, Agabiti N, Di Martino M, Bauleo L, Formoso G, Voci C, Pistelli R, Patorno E, Davoli M, on behalf of the OUTPUL study group. One-year mortality associated with COPD treatment: a comparison of tiotropium and long-acting beta2-agonists in three Italian regions: results from the OUTPUL study. Pharmacoepidemiol Drug Saf 2016;25:578-89. [Ref.ID 100264]
8.Tiene citas relacionadas Cita con resumen
Vestbo J, Anderson JA, Brook RD, Calverley PMA, Celli BR, Crim C, Martínez F, Yates J, Newby DE, SUMMIT Investigators. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet 2016;387:1817-26. [Ref.ID 100248]
9.Tiene citas relacionadas Cita con resumen
Brussele G. Vilanterol fluticasone and mortality in comorbid COPD GOLD B. Lancet 2016;387:1791-2. [Ref.ID 100246]
11. Cita con resumen
Anónimo. Umeclidinium (Incruse Ellipta) for COPD. Med Lett Drugs Ther 2015;57:63-4. [Ref.ID 99449]
12. Cita con resumen
Anónimo. Umeclidinium: another LAMA for COPD. Drug Ther Bull 2015;53:81-4. [Ref.ID 99317]
15.
Magnussen H, Disse B, Rodriguez-Roisin R, Kirsten A, Watz H, Telzlaff K, Towse L, Finnigan H, Dahl R, Decramer M, Chanez P, Wouters EFM, Calverley PMA, for the WISDOM Investigators. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 2015;371:1285-94. [Ref.ID 98480]
16.Tiene citas relacionadas Cita con resumen
Reilly JJ. Stepping down therapy in COPD. N Engl J Med 2014;371:1340-1. [Ref.ID 98125]
17.Tiene citas relacionadas Cita con resumen
Magnussen H, Disse B, Rodríguez-Roisin R, Kirsten A, Watz H, Telzlaff K, Towse L, Finnigan H, Dahl R, Decramer M, Chanez P, Wouters EFM, Calverley PMA, for the WISDOM Investigators. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 2014;371:1285-94. [Ref.ID 98124]
18. Cita con resumen
Anónimo. Relvar ellipta for asthma. Drug Ther Bull 2014;52:93-6. [Ref.ID 97880]
19.
Herath SC, Poole P. Prophylactic antibiotic therapy in chronic obstructive pulmonary disease. JAMA 2014;311:2225-6. [Ref.ID 97672]
20. Cita con resumen
Kiser TH, Allen RR, Valuck RJ, Moss M, Vandiver RW. Outcomes associated with corticosteroid dosage in critically ill patients with acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2014;189:1052-64. [Ref.ID 97567]
Seleccionar todas
 
 1 a 20 de 279 siguiente >>